ABAdrie BekkerPhD, MDSlidesetHIV17th International Workshop on Pediatrics & HIV 2025What Do We Know About Choice of Antiretrovirals for Infant Prophylaxis to Prevent Transmission? - Adrie BekkerView Slideset
RFRashida FerrandMBBS, FRCP, MSc, PhD, FMed SciSlidesetHIV17th International Workshop on Pediatrics & HIV 2025The Clinical Consequences of Premature Aging in Youth with Perinatal HIV Infection - Rashida FerrandView Slideset
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Youth Panel: New Platforms, New Possibilities - Supporting Adolescents Living with HIV in a Digital World - Ravel GatotoView Slideset
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #6 Did HIV-1 Incidence Decline During the DREAMS Program? Lack of Progress for Adolescent Girls and Young Women - Nora RosenbergView Slideset
SDSahera Dirajlal-FargoMDSlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #7 Ugandan Teenage Females with PHIV on DTG Have a Distinct Phenotype Concerning for Future Cardiometabolic Risk - Sahera Dirajlal-FargoView Slideset
BZBrian ZanoniMD, MPHSlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #9 Mental Health Challenges and Substance Use Associated with Poor Viral Suppression and Transition Readiness among Adolescents with HIV Transitioning to Adult Care - Brian ZanoniView Slideset
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #10 Outcomes of Children and Young Adolescents Receiving ART Under Family-Based DSD Model at Largest Public ART Clinic in Lilongwe, Malawi - Petros P.M. TemboView Slideset
MMMauricio MartinsBSc, PhDSlidesetHIV17th International Workshop on Pediatrics & HIV 2025 Gene Therapy and Remission - Mauricio MartinsView Slideset
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James WyncollView Slideset
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro GarciaView Slideset
HMHilda MujuruMBChB, MMed Paeds, MSc Clin EpiSlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela MujuruView Slideset
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie CollinsView Slideset
